Clinical trials: completed, sponsored by Janssen Research & Development, LLC
Hepatic Impairment
A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function
The purpose of this study is to characterize the pharmacokinetics (what the body does to the study medication) of JNJ-38518168 at approximately steady-state (stable medication levels) after administration of multiple oral 30 mg…
- Trial name
- NCT01863784
- Testing
- JNJ-38518168
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Janssen Research & Development, LLC
Arthritis, Rheumatoid
A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy
The purpose of this study is to evaluate the efficacy of ustekinumab and CNTO 1959 in reducing the signs and symptoms of disease in patients with active rheumatoid arthritis (RA) despite concomitant methotrexate (MTX) therapy and…
- Trial name
- NCT01645280
- Testing
- Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4)
- Where
- 47 sites in United States, Argentina and 9 more
- Volunteers
- 274 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of paliperidone palmitate 3 month formulation (PP3M) compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.
- Trial name
- NCT01529515
- Testing
- PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq.
- Where
- 53 sites in United States, Colombia and 6 more
- Volunteers
- 509 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
The purpose of this study is to demonstrate that a paliperidone palmitate 3 month formulation (PP3M) is as effective as the paliperidone palmitate 1 month formulation (PP1M) in the treatment of patients with schizophrenia who…
- Trial name
- NCT01515423
- Testing
- PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq.
- Where
- 174 sites in United States, Argentina and 24 more
- Volunteers
- 1,429 people
- Sponsor
- Janssen Research & Development, LLC
Colitis, Ulcerative
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to assess the safety and efficacy of golimumab administered subcutaneously (under the skin) injections in maintenance therapy.
- Trial name
- NCT00488631
- Testing
- Golimumab 50 mg, Golimumab 100 mg, Golimumab 200 mg
- Where
- 297 sites in United States, Australia and 24 more
- Volunteers
- 1,228 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants
The purpose of this study is to evaluate the safety, acceptability, pharmacokinetics (what the body does to the medication), and ex vivo (tested outside the body) pharmacodynamics (what the medication does to the body) of TMC278…
- Trial name
- NCT01656018
- Testing
- TMC278, Long acting (LA)
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Lupus Nephritis
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
The purpose of this study is to evaluate the efficacy and safety of CNTO 136 administered intravenously in patients with active, International Society of Nephrology/Renal Pathology Society Class III and IV Lupus Nephritis (LN).
- Trial name
- NCT01273389
- Testing
- CNTO 136
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 25 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations
The purpose of this study is to evaluate the pharmacokinetic (PK) (blood levels) comparability of 2 different formulations of ustekinumab, 90 milligram per milliliter (mg/mL) liquid in vial (LIV) and 5 mg/mL LIV, following a…
- Trial name
- NCT02156375
- Testing
- Ustekinumab
- Where
- 3 sites in United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
Bioavailability and Pharmacokinetics Study of Sirukumab in Healthy Male Participants
The purpose of the study is to assess the bioavailability (the extent to which a medication becomes available to the body) of subcutaneously (under the skin using a needle) administered sirukumab and to compare the…
- Trial name
- NCT02079545
- Testing
- Sirukumab (IV infusion), Sirukumab (SC injection with PFS-U), Sirukumab (SC injection with PFS-AI)
- Where
- 2 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The purpose of this study is to assess the efficacy and safety of CNTO6785 in participants with active rheumatoid arthritis (RA) despite methotrexate (MTX) therapy.
- Trial name
- NCT01909427
- Testing
- CNTO 6785 200 mg, CNTO 6785 100 mg, CNTO 6785 50 mg
- Where
- 32 sites in Argentina, Colombia and 5 more
- Volunteers
- 257 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants
The purpose of this study is to evaluate effect of multiple-dose administration of JNJ-42847922 on the single-dose pharmacokinetics of oral midazolam and single-dose pharmacokinetics and pharmacodynamics of (R)- and (S)-warfarin…
- Trial name
- NCT02617810
- Testing
- JNJ-42847922, Midazolam, Warfarin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Neoplasm Metastases, Hepatic Insufficiency
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
The purpose of this study is to characterize the pharmacokinetics (blood levels) of trabectedin after administration to patients with advanced malignancies and hepatic (liver) dysfunction.
- Trial name
- NCT01273493
- Testing
- Trabectedin, Dexamethasone
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 15 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants
The purpose of the study is to evaluate effect of JNJ-42847922 on sleep latency (latency to persistent sleep) in participants with major depressive disorder who are stably treated with selective serotonin reuptake…
- Trial name
- NCT02067299
- Testing
- JNJ-42847922
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 20 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants
The purpose of this study is to evaluate the effect of steady-state concentrations of JNJ-63623872 on the single-dose pharmacokinetics of pitavastatin in healthy participants.
- Trial name
- NCT02595268
- Testing
- Pitavastatin, JNJ-63623872
- Where
- Belgium
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Pain, Burning, Pain, Crushing
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain
The purpose of this study is to compare the safety and effectiveness of JNJ-42160443 with placebo in the treatment of chronic, moderate to severe cancer-related pain in terminally ill patients with a diagnosis of active cancer.
- Conditions
- Pain, Burning, Pain, Crushing, Pain, Migratory, Pain, Radiating
- Trial name
- NCT00929188
- Testing
- JNJ-42160443
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants
The purpose of this study is to determine the bioequivalence (equivalence of pharmacokinetic parameters) of 2 abiraterone acetate coated tablet formulations with respect to the current commercial abiraterone acetate uncoated…
- Trial name
- NCT02230046
- Testing
- Abiraterone acetate (Treatment A), Abiraterone acetate (Treatment B)
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Allergic Rhinitis
Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine
The purpose of this study is to evaluate the effects of allergic rhinitis (group of symptoms affecting the nose) and co-administration of mometasone or oxymetazoline on the pharmacokinetics (explores what the body does to the…
- Trial name
- NCT02154334
- Testing
- Esketamine, Mometasone, Oxymetazoline
- Where
- Germany
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults
The purpose of this study is to assess the relative bioavailability (the extent to which a drug or other substance becomes available to the body) of ibrutinib in healthy adults following single oral dose administration of…
- Trial name
- NCT02390609
- Testing
- Ibrutinib (Treatment A) [Reference], Ibrutinib (Treatment B), Ibrutinib (Treatment C)
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Neoplasms, Neoplasms, Ovarian
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
The purpose of this study is to support the qualification of a replacement manufacturing site for DOXIL/CAELYX (doxorubicin HCL).
- Conditions
- Neoplasms, Neoplasms, Ovarian, Neoplasms, Breast, Advanced or Refractory Solid Malignancies
- Trial name
- NCT01815294
- Testing
- DOXIL/CAELYX (doxorubicin) Treatment Sequence AB, DOXIL/CAELYX (doxorubicin) Treatment Sequence BA
- Where
- 8 sites in United States, Belgium and 2 more
- Volunteers
- 54 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates
The purpose of this study is to assess the effects of single and multiple once daily doses of 50 milligram (mg) of JNJ-54861911 on pharmacokinetics (PK) (study of the way a drug enters and leaves the blood and tissues over time)…
- Trial name
- NCT02211079
- Testing
- JNJ-54861911, Caffeine, Midazolam
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC